Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-05
2010-02-16
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S268400, C546S290000, C546S304000
Reexamination Certificate
active
07662839
ABSTRACT:
A compound of formula (I):or a salt, or chemically protected form thereof, wherein: R5is an optionally substituted phenyl;A is wherein Q is N; R3is selected from H, F, Cl and optionally substituted C1-4alkyl, C1-4alkoxy, C5-7aryl, and C5-7aryl-C1-4alkyl groups; R4is selected from H, F, Cl and optionally substituted C1-4alkyl, C1-4alkoxy, C5-7aryl, and C5-7aryl-C1-4alkyl groups; R6is selected from H, F, Cl, and optionally substituted C1-4alkyl, C1-4alkoxy, C5-7aryl, and C5-7aryl-C1-4alkyl groups;D is selected from:B is selected from the group consisting of:Where RN′is selected from H and C1-4alkyl; where one of RP3and RP4is —Cm-alkylene-R2and the other of RP3and RP4is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally, when RP3is —Cm-alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2is tetrazol-5-yl, m+n may be 0; or where one of RP3and RP4is —O—CH2—R2, and the other of RP3and RP4is H, n is 0; RNis H or optionally substituted C1-4alkyl; R2is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.
REFERENCES:
patent: 5576347 (1996-11-01), Sredni et al.
patent: 5939332 (1999-08-01), Lee et al.
patent: 6562868 (2003-05-01), Stjernschantz et al.
patent: 2005/0256170 (2005-11-01), Oxford et al.
patent: 0 496 378 (1992-07-01), None
patent: 2 293 101 (1996-03-01), None
patent: WO 98/27976 (1998-07-01), None
patent: WO 98/34916 (1998-08-01), None
patent: WO 00/27823 (2000-05-01), None
patent: WO 00/31084 (2000-06-01), None
patent: WO 00/40248 (2000-07-01), None
patent: WO 01/46140 (2001-06-01), None
patent: WO 01/85167 (2001-11-01), None
patent: WO 02/24647 (2002-03-01), None
patent: WO 03/032972 (2003-04-01), None
patent: WO 03/037433 (2003-05-01), None
patent: WO 03/040126 (2003-05-01), None
patent: WO 03/045371 (2003-06-01), None
patent: WO 2004/007439 (2003-08-01), None
patent: WO 2004/012656 (2004-02-01), None
patent: WO 2005/061449 (2005-07-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Patani, George A. Bioisosterism: A rational Approach in Drug Design. Chem. Rev. 96 (1996) 3147-3176.
Youssefyeh, Raymond D. Development of a Novel Series of (2-Quinolinylmethoxy)phenyl-Containing Compounds as High-Affinity Leukotriene Receptor Antagonists. 1. Initial Structure-Activity Relationships. J. Med. Chem. 33 (1990) 1186-1194.
U.S. Appl. No. 11/019,133, filed Dec. 2004, Borman et al.
Berge et al, Journal of Pharmaceutical Sciences, 1977, vol. 66, No. 1, pp. 1-19.
Griffiths et al, Current Drug Targets—Inflammation & Allergy, 2004, vol. 3, pp. 157-161.
Lebwohl, The Lancet, 2003, vol. 361, pp. 1197-1204.
Nataraj et al, The Journal of Clinical Investigation, 2001, vol. 108, No. 8, pp. 1229-1235.
Salim et al, Current Opinion in Investigational Drugs, 2001, 2(11):1546-1548.
Tilley et al, Am. J. Physiol. Lung Cell Mol. Physiol, 2003, 284:599-606.
Chemical Abstract Accession No. 2003:3915608, Otava Stock Chemicals Catalogue, Oct. 26, 2003, compound with CAS Registry No. 620542-88-3.
Chemical Abstract Accession No. 2003:3848742, Akos Samples Catalogue, Feb. 9, 2004, compound with CAS Registry No. 618413-90-4.
Chemical Abstract Accession No. 2003:3849399, Akos Samples Catalogue, Feb. 9, 2004, compound with CAS Registry No. 618404-52-7.
Chemical Abstract Accession No. 2003:3849331, Akos Samples Catalogue, Feb. 9, 2004, compound with CAS Registry No. 618401-55-1.
Uesato et al, Bioorganic & Medicinal Chemistry Letters, 2002, vol. 12, pp. 1347-1349.
Ashton Mark Richard
Boyd Edward Andrew
Brunton Shirley Ann
Clark David Edward
Clark Kenneth Lyle
Asterand UK Limited
Bott Cynthia M.
Honigman Miller Schwartz & Cohn LLP
Saeed Kamal A
Shterengarts Samantha L
LandOfFree
EP2 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EP2 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP2 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197198